A novel prostate cancer therapeutic strategy using icaritin-activated arylhydrocarbon-receptor to co-target androgen receptor and its splice variants

Carcinogenesis

Volumn 36, Issue 7, 2015, Pages 757-768

  Sun, Feng ^a   Indran, Inthrani R ^a   Zhang, Zhi Wei ^a   Tan, M H Eileen ^a   Li, Yu ^a   Lim, Z L Ryan ^a   Hua, Rui ^a   Yang, Chong ^a,b   Soon, Fen Fen ^a   Li, Jun ^a   Xu, H Eric ^c   Cheung, Edwin ^b   Yong, Eu Leong ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b GENOME INSTITUTE OF SINGAPORE   (Singapore)

^c VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; AROMATIC HYDROCARBON RECEPTOR; FLAVONOID; ICARITIN; PROSTATE SPECIFIC ANTIGEN; PROTEASOME; UBIQUITIN CONJUGATING ENZYME; UBIQUITIN CONJUGATING ENZYME E2C; UNCLASSIFIED DRUG; AR PROTEIN, HUMAN; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; UBE2C PROTEIN, HUMAN; UBIQUITIN;

ALTERNATIVE RNA SPLICING; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE CONTROL; GENE TARGETING; GENETIC VARIABILITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN DEGRADATION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; TRANSACTIVATION; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NONOBESE DIABETIC MOUSE; PATHOLOGY; PROSTATIC NEOPLASMS; RNA SPLICING; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; FLAVONOIDS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KALLIKREINS; MALE; MICE, INBRED NOD; MOLECULAR TARGETED THERAPY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN STABILITY; RECEPTORS, ANDROGEN; RECEPTORS, ARYL HYDROCARBON; RNA SPLICING; SIGNAL TRANSDUCTION; UBIQUITIN; UBIQUITIN-CONJUGATING ENZYMES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84941632263     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgv040     Document Type: Article

References (43)

1. Huggins, C. et al. (1972) Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA. Cancer J. Clin., 22, 232-240.
2. Harris, W.P. et al. (2009) Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat. Clin. Pract. Urol., 6, 76-85.
3. Dason, S. et al. (2013) Defining a new testosterone threshold for medical castration: Results from a prospective cohort series. Can. Urol. Assoc. J., 7, E263-E267.
4. Montgomery, R.B. et al. (2008) Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res., 68, 4447-4454.
5. Chen, C.D. et al. (2004) Molecular determinants of resistance to antiandrogen therapy. Nat. Med., 10, 33-39.
6. Taplin, M.E. et al. (1995) Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med., 332, 1393-1398.
7. Xu, J. et al. (2009) Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nat. Rev. Cancer, 9, 615-630.
8. Dehm, S.M. et al. (2008) Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res., 68, 5469-5477.
9. Hu, R. et al. (2009) Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res., 69, 16-22.
10. Scher, H.I. et al. AFFIRM Investigators. (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med., 367, 1187-1197.
11. Dehm, S.M. et al. (2011) Alternatively spliced androgen receptor variants. Endocr. Relat. Cancer, 18, R183-R196.
12. Antonarakis, E.S. et al. (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med., 371, 1028-1038.
13. Li, Y. et al. (2013) Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res., 73, 483-489.
14. Hu, R. et al. (2012) Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res., 72, 3457-3462.
15. (2010) Chinese materia medica and prepared slices of Chinese crude Drugs. In Wang, Z.T., et al. (eds.), Pharmacopoeia of the People's Republic of China. vol. 1. China Medical Science Press, Beijing, China, pp. 169-170.
16. Tiong, C.T. et al. (2012) A novel prenylflavone restricts breast cancer cell growth through AhR-mediated destabilization of ERa protein. Carcinogenesis, 33, 1089-1097.
17. Ohtake, F. et al. (2007) Dioxin receptor is a ligand-dependent E3 ubiquitin ligase. Nature, 446, 562-566.
18. Clegg, N.J. et al. (2012) ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res., 72, 1494-1503.
19. Huang, X. et al. (2007) A novel anticancer agent, icaritin, induced cell growth inhibition, G1 arrest and mitochondrial transmembrane potential drop in human prostate carcinoma PC-3 cells. Eur. J. Pharmacol., 564, 26-36.
20. Wong, S.P. et al. (2007) Ultrasensitive cell-based bioassay for the measurement of global estrogenic activity of flavonoid mixtures revealing additive, restrictive, and enhanced actions in binary and higher order combinations. Assay Drug Dev. Technol., 5, 355-362.
21. Loy, C.J. et al. (2003) Filamin-A fragment localizes to the nucleus to regulate androgen receptor and coactivator functions. Proc. Natl. Acad. Sci. U. S. A., 100, 4562-4567.
22. Chng, K.R. et al. (2012) A transcriptional repressor co-regulatory network governing androgen response in prostate cancers. EMBO J., 31, 2810-2823.
23. Stephenson, R.A. et al. (1992) Metastatic model for human prostate cancer using orthotopic implantation in nude mice. J. Natl. Cancer Inst., 84, 951-957.
24. Lai, K.P. et al. (2013) New therapeutic approach to suppress castrationresistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells. Am. J. Pathol., 182, 460-473.
25. Tran, C. et al. (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science, 324, 787-790.
26. Jaworski, T. (2006) Degradation and beyond: control of androgen receptor activity by the proteasome system. Cell. Mol. Biol. Lett., 11, 109-131.
27. Sheflin, L. et al. (2000) Inhibiting proteasomes in human HepG2 and LNCaP cells increases endogenous androgen receptor levels. Biochem. Biophys. Res. Commun., 276, 144-150.
28. Lin, H.K. et al. (2002) Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J., 21, 4037-4048.
29. Hsu, C.L. et al. (2005) Androgen receptor (AR) NH2-and COOH-terminal interactions result in the differential influences on the AR-mediated transactivation and cell growth. Mol. Endocrinol., 19, 350-361.
30. Sato, N. et al. (1997) A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice. Cancer Res., 57, 1584-1589.
31. Wong, S.P. et al. (2009) Pharmacokinetics of prenylflavonoids and correlations with the dynamics of estrogen action in sera following ingestion of a standardized Epimedium extract. J. Pharm. Biomed. Anal., 50, 216-223.
32. Andersen, R.J. et al. (2010) Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell, 17, 535-546.
33. Amin, K.S. et al. (2014) A naturally derived small molecule disrupts ligand-dependent and ligand-independent androgen receptor signaling in human prostate cancer cells. Mol. Cancer Ther., 13, 341-352.
34. Myung, J.K. et al. (2013) An androgen receptor N-terminal domain antagonist for treating prostate cancer. J. Clin. Invest., 123, 2948-2960.
35. Liu, C. et al. (2014) Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castrationresistant prostate cancer. Clin. Cancer Res., 20, 3198-3210.
36. Liao, X. et al. (2005) Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer. Mol. Cancer Ther., 4, 505-515.
37. Lu, S. et al. (1999) Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter. Mol. Endocrinol., 13, 376-384.
38. Rokhlin, O.W. et al. (2005) Androgen regulates apoptosis induced by TNFR family ligands via multiple signaling pathways in LNCaP. Oncogene, 24, 6773-6784.
39. Nguyen, T.V. et al. (2005) Androgens activate mitogen-activated protein kinase signaling: role in neuroprotection. J. Neurochem., 94, 1639-1651.
40. Wen, S. et al. (2014) Androgen receptor (AR) positive vs negative roles in prostate cancer cell deaths including apoptosis, anoikis, entosis, necrosis and autophagic cell death. Cancer Treat. Rev., 40, 31-40.
41. Morrow, D. et al. (2004) Aryl hydrocarbon receptor-mediated inhibition of LNCaP prostate cancer cell growth and hormone-induced transactivation. J. Steroid Biochem. Mol. Biol., 88, 27-36.
42. Jana, N.R. et al. (1999) Cross-talk between 2,3,7,8-tetrachlorodibenzo-p-dioxin and testosterone signal transduction pathways in LNCaP prostate cancer cells. Biochem. Biophys. Res. Commun., 256, 462-468.
43. Chamie, K. et al. (2008) Agent Orange exposure, Vietnam War veterans, and the risk of prostate cancer. Cancer, 113, 2464-2470.